Covered recipient · General Payments record
JAMES D WOLFE
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$916.69
52 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $916.69 | 52 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $444.06 | 27 |
| AstraZeneca Pharmaceuticals LP | $344.15 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $80.37 | 4 |
| Regeneron Healthcare Solutions, Inc. | $24.53 | 1 |
| kaleo, Inc. | $23.58 | 1 |
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES D WOLFE
NPI 1194733428 · CMS profile ID 145083
Allopathic & Osteopathic Physicians / Allergy & Immunology
SAN JOSE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1194733428?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES D WOLFE, NPI 1194733428, CMS profile ID 145083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194733428?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JAMES D WOLFE, NPI 1194733428, CMS profile ID 145083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194733428?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JAMES D WOLFE, NPI 1194733428, CMS profile ID 145083, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1194733428?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
52 matching records · $916.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–52 of 52.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $13.80 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802769465 | CMS |
| GlaxoSmithKline, LLC. | $1.61 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803151389 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $582,384.02 | 40 |
| PY2024 | Principal investigator | $382,536.18 | 47 |
| PY2023 | Principal investigator | $352,822.08 | 50 |
| PY2022 | Principal investigator | $230,266.14 | 3 |
| PY2021 | Principal investigator | $93,915.03 | 3 |
| PY2020 | Principal investigator | $273,392.04 | 20 |
| PY2019 | Principal investigator | $449,704.45 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
40 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $2,892.76 | 12/25/2025 | Non-covered Recipient Entity CRN Clinical Research Network LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228746586 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,590.00 | 12/22/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138104 |
| Principal investigator 1 | PFIZER INC. | $3,250.33 | 11/27/2025 | Non-covered Recipient Entity CRN Clinical Research Network LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228728211 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,435.50 | 11/17/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138081 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,583.12 | 11/14/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185545099 |
| Principal investigator 1 | PFIZER INC. | $3,250.33 | 11/04/2025 | Non-covered Recipient Entity CRN Clinical Research Network LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228738399 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,008.31 | 10/23/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183872 |
| Principal investigator 1 | PFIZER INC. | $10,852.87 | 10/08/2025 | Non-covered Recipient Entity CRN Clinical Research Network LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228758025 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,600.00 | 10/06/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138051 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,570.00 | 09/08/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138038 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,510.34 | 08/22/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183876 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $372.26 | 08/18/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138027 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,020.00 | 08/13/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545101 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,340.00 | 08/11/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138004 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,300.00 | 08/07/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545111 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $55,586.62 | 07/22/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185545107 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $110,897.31 | 07/22/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185545113 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,872.58 | 07/18/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192152296 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,443.60 | 07/14/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226137963 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,073.00 | 07/11/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183868 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $61,762.74 | 06/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185545119 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,073.90 | 06/16/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138229 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,607.70 | 06/09/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138225 |
| Principal investigator 1 | PFIZER INC. | $13,542.00 | 06/03/2025 | Non-covered Recipient Entity CRN Clinical Research Network LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228776411 |
| Principal investigator 1 | AstraZeneca UK Limited | $29,656.10 | 05/19/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185545117 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,455.70 | 05/12/2025 | Non-covered Recipient Entity Crn Clinical Research Network LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138198 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $75,687.69 | 05/08/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185545105 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,944.95 | 04/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545103 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,411.04 | 04/09/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545115 |
| Principal investigator 1 | CIPLA USA INC. | $1,023.36 | 04/01/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SANTA CLARA VALLEY RESEARCH CENTER | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932231 |
| Principal investigator 1 | Chiesi USA, Inc. | $500.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398278 |
| Principal investigator 1 | Chiesi USA, Inc. | $968.79 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398282 |
| Principal investigator 1 | Chiesi USA, Inc. | $600.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398286 |
| Principal investigator 1 | Chiesi USA, Inc. | $118.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398289 |
| Principal investigator 1 | Chiesi USA, Inc. | $118.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398293 |
| Principal investigator 1 | Chiesi USA, Inc. | $118.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398297 |
| Principal investigator 1 | Chiesi USA, Inc. | $118.00 | 03/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234398301 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,280.00 | 03/13/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185545121 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $51,792.29 | 01/09/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF NORTHERN CALIFORNIA | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185545109 |
| Principal investigator 1 | CIPLA USA INC. | $14,156.83 | 01/07/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SANTA CLARA VALLEY RESEARCH CENTER | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932239 |